Micro Aftermath Archived

BDX price target lowered

Activity declining — narrative losing relevance.

Score 0.3

Velocity ▲ 0.0

Articles 9

Sources 1

Top Movers

Ticker	Sector	Change
BDX	Health Care	+23.9%

Sentiment Timeline

Sector Performance

Event Timeline

May 19, 2026 Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock? Neutral

May 17, 2026 Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target Bullish

May 07, 2026 BD uplifts FY26 revenue outlook based on steady portfolio performance Bullish

Apr 24, 2026 Becton Dickinson and Company (BDX): Gold Standard Defensive Stock Neutral

Apr 21, 2026 What You Need to Know Ahead of Becton, Dickinson and Company's Earnings … Neutral

Apr 19, 2026 RBC Trims Becton Dickinson (BDX) Outlook despite Stable MedTech Demand Bearish

Apr 15, 2026 Mizuho Lowers Medtronic (MDT) Target Ahead of Q1, Maintains Positive View Neutral

Apr 04, 2026 Baird Lowers its Price Target on Nyxoah SA (NYXH) to $4.62 from … Bearish

Mar 25, 2026 Argus Lowers its Price Target on Becton, Dickinson and Company (BDX) to … Neutral

Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock? Yahoo Finance · May 19, 2026 Mixed Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target Yahoo Finance · May 17, 2026 Mixed RBC Trims Becton Dickinson (BDX) Outlook despite Stable MedTech Demand Yahoo Finance · Apr 19, 2026 Mixed

Top Movers

Ticker	Sector	Change
BDX	Health Care	+23.9%

🤖 AI Overview

What happened: On April 14, RBC Capital lowered its price target on Becton, Dickinson and Company (BDX) to $175 from $195, maintaining a Sector Perform rating. Despite stable medtech demand, RBC cited valuation concerns. In contrast, BDX was recently included among the top 10 healthcare stocks with the highest dividends. Meanwhile, BDX uplifted its FY26 revenue outlook based on steady portfolio performance, reporting a 5.2% YoY increase in Q2 2026 revenues.

Market impact: The price target reductions by RBC and Argus (to $180) suggest a potential repricing of BDX's valuation, affecting investors seeking high dividend yields. However, BDX's bullish outlook on FY26 revenues indicates continued demand for its medical supplies and devices, benefiting the broader medtech sector.

What to watch next: BDX's upcoming earnings release (scheduled, but date not specified in the provided articles) will provide further clarity on its financial performance and outlook. Additionally, any updates to BDX's dividend policy or guidance on its transition towards a pure-play medtech company will be crucial for investors.

AI Overview as of May 08, 2026

Timeline

First SeenMar 25, 2026

Last UpdatedMar 25, 2026

BDX price target lowered

Top Movers

Sentiment Timeline

Sector Performance

Event Timeline

Related Articles